Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKAR | P32238 | 13/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.43 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.43 |
| ▸ | MCTS1 | Q9ULC4 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9998530 | 0.90 | CCKAR (0.57) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9998587 | 0.86 | CCKAR (0.55) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9998570 | 0.83 | CCKAR (0.51) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9998578 | 0.82 | RXRA (0.49) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9998771 | 0.81 | ALOX5 (0.55) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9998797 | 0.81 | RXRA (0.49) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9988463 | 0.79 | RXRA (0.54) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9996784 | 0.79 | RXRA (0.49) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9998397 | 0.78 | CCKAR (0.46) | CCKARALOX5PTGS2RXRARXRB | |
| SCHEMBL9999152 | 0.78 | CCKAR (0.49) | CCKARALOX5PTGS2RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011161645-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-29 | — | — | WO | disclosed |